Regeneron beats fourth-quarter revenue estimates By Reuters



© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo

(Reuters) -Regeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker’s preliminary estimates target.

Eylea sales were $1.46 billion, including $123 million from the higher dose version of the drug, in line with the company’s previously laid out targets in January.

Total revenue was $3.43 billion, beating analysts’ estimates of $3.29 billion, according to LSEG data.

The company also said it has submitted its application to U.S. Food and Drug Administration to expand use of its eczema treatment Dupixent, in patients with a type of lung disease known as chronic obstructive pulmonary disease.



Source link

Leave a Comment